Microbial Science

Probiotic shows promise for treating intestinal inflammation disorders

Researchers found that the probiotic bacterial species produced a rapid and marked increase in the function of the cells

August 18, 2021
The Scitech

Dr. Thomas Ma, professor and chair of the Department of Medicine at Penn State College of Medicine, leads a research team exploring how a probiotic may be used to treat intestinal inflammation disorders like inflammatory bowel disease. IMAGE: Penn State Health

A study by Penn State College of Medicine researchers suggests that a type of probiotic found in various brands of yogurt may help with treating certain intestinal inflammation disorders.

Dr. Thomas Ma, professor and chair of the Department of Medicine at the College of Medicine and Penn State Health Milton S. Hershey Medical Center, led a team that examined more than 20 probiotic bacteria to determine their ability to increase intestinal barrier function. Intestinal barriers protect against harmful biological agents that cause diseases like inflammatory bowel disease (IBD).

The research team found that the probiotic bacterial species L. acidophilus, specifically the LA1 strain, produced a rapid and marked increase in the function of the cells that make up the intestinal barrier in studies of animal cells that were grown in a lab. During proof-of-concept studies, Ma determined that LA1 enhanced the intestinal barrier in the small intestines and colons of mice. Treatment studies after onset of intestinal inflammation or colitis found that LA1 was also effective in the healing of intestinal barrier and colitis.

“Our data indicate that LA1 is able to prevent colonic inflammation formation and promote colitis healing,” Ma said. “The implications of these findings are that this bacterial strain could be used in a wide variety of intestinal permeability disorders, including IBD [inflammatory bowel disease], celiac disease, alcoholic liver disease, non-alcoholic fatty liver disease and necrotizing enterocolitis, to treat inflammation associated with leaky gut.”

Ma is in the process of getting approval from the U.S. Food and Drug Administration to conduct a clinical trial.

Rana Al-Sadi, Prashant Nighot, Meghali Nighot and Mohammad Haque of Penn State College of Medicine and Manmeet Rawat of the University of New Mexico School of Medicine also contributed to this research.

This research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases and the Crohn’s and Colitis Foundation of America. The researchers declare no conflicts of interest.

(Source: Penn State University news release)